Title:
siRNA AND PHARMACEUTICAL COMPOSITION, AND PROPHYLACTIC AND/OR THERAPEUTIC AGENT
Document Type and Number:
WIPO Patent Application WO/2022/092279
Kind Code:
A1
Abstract:
[Problem] To provide a pharmaceutical composition containing siRNA, as an active ingredient, that suppresses the BAZF expression. Specifically, the pharmaceutical composition is a prophylactic and/or therapeutic agent that, through suppressing the BAZF expression, prevents and/or treats diseases associated with the VEGF action that promotes neoangiogenesis, e.g., various intraocular neoangiogenesis diseases including diabetic retinopathy such as proliferative diabetic retinopathy, retinopathy of prematurity, retinal branched vein occlusion, central retinal vein occlusion, neovascular glaucoma, neovascular maculopathy, diabetic macular edema, and age-related macular degeneration. [Solution] Provided are: siRNA characterized in that the nucleotide sequence represented by SEQ ID NO: 1 is the target gene sequence; and a pharmaceutical composition that contains the siRNA as an active ingredient.
More Like This:
| JP2023515466 | Methods for reducing HTT expression |
| JP2019532640 | HLA class I-deficient NK-92 cells with reduced immunogenicity |
| JP2024505151 | lipid nanoparticle spherical nucleic acid |
Inventors:
HARA HIDEAKI (JP)
NAKAMURA SHINSUKE (JP)
YUNOKI KAORI (JP)
SAWA MASAAKI (JP)
NAKAMURA SHINSUKE (JP)
YUNOKI KAORI (JP)
SAWA MASAAKI (JP)
Application Number:
PCT/JP2021/040073
Publication Date:
May 05, 2022
Filing Date:
October 29, 2021
Export Citation:
Assignee:
CARNA BIOSCIENCES INC (JP)
HARA HIDEAKI (JP)
NAKAMURA SHINSUKE (JP)
HARA HIDEAKI (JP)
NAKAMURA SHINSUKE (JP)
International Classes:
C12N15/113; A61K31/713; A61K48/00; A61P9/10; A61P27/02; A61P27/06
Domestic Patent References:
| WO2010018764A1 | 2010-02-18 |
Foreign References:
| JP2011115109A | 2011-06-16 |
Other References:
BUCHBERGER ELISABETH, PAYRHUBER DIETMAR, HARCHI MIRIAM EL, ZAGRAPAN BRANISLAV, SCHEUBA KATHARINA, ZOMMER ANNA, BUGYIK EDINA, DOME : "Inhibition of the transcriptional repressor complex Bcl-6/BCoR induces endothelial sprouting but does not promote tumor growth", ONCOTARGET, vol. 8, no. 1, 3 January 2017 (2017-01-03), pages 552 - 564, XP055926371, DOI: 10.18632/oncotarget.13477
Attorney, Agent or Firm:
YOSHIDA Tomoko (JP)
Download PDF:
Previous Patent: AUTHENTICATION METHOD, AUTHENTICATION SYSTEM, AND PROGRAM
Next Patent: INK COMPOSITION
Next Patent: INK COMPOSITION